Geron Corporation, a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 1990, Geron has made significant strides in the field of telomerase biology, positioning itself as a leader in the development of telomerase inhibitors. The company’s flagship product, imetelstat, is a first-in-class telomerase inhibitor that targets cancer stem cells, offering a unique approach to treating various malignancies. Geron’s commitment to advancing cancer treatment has garnered attention within the industry, as it continues to explore new therapeutic avenues and expand its operational reach. With a strong emphasis on research and development, Geron Corporation remains at the forefront of biopharmaceutical innovation, striving to improve patient outcomes in oncology.
How does Geron Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Geron Corporation's score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Geron Corporation, headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The absence of emissions data suggests that the company may not have publicly disclosed its carbon footprint or climate commitments at this time. As a result, there are no specific figures to report regarding Scope 1, 2, or 3 emissions, nor any significant achievements in emissions reduction. Without concrete data, it is unclear how Geron Corporation aligns with industry standards for climate action or whether it has set any science-based targets for emissions reductions. In the context of corporate climate commitments, it is essential for companies like Geron to establish clear goals and transparent reporting to contribute effectively to global climate efforts.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Geron Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
